Diasorin SpA
DIA: XMIL (ITA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| ^fk | LOCK|<%xC@ | LOCK|VL&$^F |
Structural Headwinds Weigh on Outlook for Diasorin; New Products Support Growth
Business Strategy and Outlook
Diasorin is a niche player in the fragmented in-vitro diagnostics market, with a strong focus on specialty immunodiagnostics. The company provides testing equipment and reagents, creating recurring sales opportunities from its installed base. Diasorin benefited from the covid pandemic, with related sales reaching 30% of the company's total sales, which have subsequently declined sharply, now accounting for 1% of sales.
